Literature DB >> 27489178

Acute migraine medication adherence, migraine disability and patient satisfaction: A naturalistic daily diary study.

Elizabeth K Seng1,2,3, Matthew S Robbins2,3, Robert A Nicholson4,5.   

Abstract

Objective To examine the influence of acute migraine medication adherence on migraine disability and acute medication satisfaction. Methods Adults with migraine completed three months of daily electronic diaries assessing headache symptoms, acute medication taken, acute medication satisfaction, and daily migraine disability. Repeated measures mixed-effects models examined the effect of initial medication type [migraine-specific medication (MSM) vs. over-the-counter analgesic (OTC) vs. an opiate/barbiturate], the severity of pain at dosing, and their interaction with daily migraine disability and satisfaction with acute medication. Results Participants (N = 337; 92.5% female; 91.1% Caucasian, non-Hispanic; 84.0% with episodic migraine) recorded 29,722 diary days. Participants took acute medication on 96.5% of 8090 migraine days. MSM was most frequently taken first (58%), followed by OTC (29.9%) and an opiate/barbiturate (12.1%). Acute medication was most frequently taken when pain was mild (41.2%), followed by moderate (37.7%) and severe pain (11.4%). Initially dosing with MSM while pain was mild was associated with the lowest daily disability [medication × pain at dosing F (4, 6336.12) = 58.73, p < .001] and highest acute medication satisfaction [medication × pain at dosing F (4, 3867.36) = 24.00, p < .001]. Conclusion Using an MSM (triptan or ergot) first was associated with the lowest migraine disability and highest acute medication satisfaction.

Entities:  

Keywords:  Migraine; acute drug therapy; adherence; disability; patient satisfaction

Mesh:

Substances:

Year:  2016        PMID: 27489178      PMCID: PMC5329165          DOI: 10.1177/0333102416663459

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  23 in total

1.  Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  S D Silberstein
Journal:  Neurology       Date:  2000-09-26       Impact factor: 9.910

2.  The International Classification of Headache Disorders: 2nd edition.

Authors: 
Journal:  Cephalalgia       Date:  2004       Impact factor: 6.292

3.  Assessing the impact of migraine onset on work productivity.

Authors:  Stephen H Landy; M Chris Runken; Christopher F Bell; Rachel L Higbie; Lisa S Haskins
Journal:  J Occup Environ Med       Date:  2011-01       Impact factor: 2.162

4.  Optimal use of acute headache medication: a qualitative examination of behaviors and barriers to their performance.

Authors:  Elizabeth K Seng; Kenneth A Holroyd
Journal:  Headache       Date:  2013-06-28       Impact factor: 5.887

5.  Reliability of the migraine disability assessment score in a population-based sample of headache sufferers.

Authors:  W F Stewart; R B Lipton; K Kolodner; J Liberman; J Sawyer
Journal:  Cephalalgia       Date:  1999-03       Impact factor: 6.292

6.  Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study.

Authors:  Seymour Diamond; Marcelo E Bigal; Stephen Silberstein; Elizabeth Loder; Michael Reed; Richard B Lipton
Journal:  Headache       Date:  2007-03       Impact factor: 5.887

7.  An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score.

Authors:  W F Stewart; R B Lipton; J Whyte; A Dowson; K Kolodner; J N Liberman; J Sawyer
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

8.  Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials.

Authors:  R K Cady; F Sheftell; R B Lipton; S O'Quinn; M Jones; D G Putnam; A Crisp; A Metz; S McNeal
Journal:  Clin Ther       Date:  2000-09       Impact factor: 3.393

Review 9.  Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.

Authors:  S Holland; S D Silberstein; F Freitag; D W Dodick; C Argoff; E Ashman
Journal:  Neurology       Date:  2012-04-24       Impact factor: 9.910

Review 10.  Overuse of acute migraine medications and migraine chronification.

Authors:  Marcelo E Bigal; Richard B Lipton
Journal:  Curr Pain Headache Rep       Date:  2009-08
View more
  6 in total

1.  Does Mindfulness-Based Cognitive Therapy for Migraine Reduce Migraine-Related Disability in People with Episodic and Chronic Migraine? A Phase 2b Pilot Randomized Clinical Trial.

Authors:  Elizabeth K Seng; Alexandra B Singer; Christopher Metts; Amy S Grinberg; Zarine S Patel; Maya Marzouk; Lauren Rosenberg; Melissa Day; Mia T Minen; Richard B Lipton; Dawn C Buse
Journal:  Headache       Date:  2019-09-26       Impact factor: 5.887

2.  Cross-Sectional Evaluation of the Psychometric Properties of the Headache-Specific Locus of Control Scale in People With Migraine.

Authors:  Amy S Grinberg; Elizabeth K Seng
Journal:  Headache       Date:  2019-02-19       Impact factor: 5.887

3.  Response to Mindfulness-Based Cognitive Therapy Differs Between Chronic and Episodic Migraine.

Authors:  Elizabeth K Seng; Alexandra B Conway; Amy S Grinberg; Zarine S Patel; Maya Marzouk; Lauren Rosenberg; Christopher Metts; Melissa A Day; Mia T Minen; Dawn C Buse; Richard B Lipton
Journal:  Neurol Clin Pract       Date:  2021-06

4.  Naturalistic assessment of patterns and predictors of acute headache medication use among women with comorbid migraine and overweight or obesity.

Authors:  Kathryn E Smith; J Graham Thomas; Kristine J Steffen; Richard B Lipton; Samantha G Farris; Jelena M Pavlovic; Dale S Bond
Journal:  Transl Behav Med       Date:  2021-08-13       Impact factor: 3.046

5.  Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study.

Authors:  Todd J Schwedt; Aftab Alam; Michael L Reed; Kristina M Fanning; Sagar Munjal; Dawn C Buse; David W Dodick; Richard B Lipton
Journal:  J Headache Pain       Date:  2018-05-24       Impact factor: 7.277

6.  Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial.

Authors:  Denise E Chou; Marianna Shnayderman Yugrakh; Dana Winegarner; Vernon Rowe; Deena Kuruvilla; Jean Schoenen
Journal:  Cephalalgia       Date:  2018-11-17       Impact factor: 6.292

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.